The efficacy of intra-articular HYADD4-G injection in the treatment of femoroacetabular impingement: results at one year follow up.

OBJECTIVE: Femoroacetabular impingement (FAI) is a condition that has been increasingly recognized as a source of hip pain and a possible risk factor to early development of hip osteoarthritis (OA). To our knowledge, the use of HA in the treatment of femoroacetabular FAI has been investigated only by two studies, both using a high molecular weight HA. The aim of this study was to evaluate the efficacy of two weekly injections of an hexadecylamide derivative of HA (HYADD4-G, HYMOVIS, Fidia Farmaceutici) in FAI.
METHODS: All patients received two weekly intra-articular injections of Hymovis at baseline and after 7 days. Clinical and functional assessments were performed at baseline and was repeated after 1, 3, 6 and 12 months. Functional measures included visual analogue scale (VAS) for pain, Harris Hip score (HHS), Lequesne Index (LI), Tegner activity level scale (TALS) and monthly consumption of nonsteroidal anti-inflammatory drugs (NSAIDs).
RESULTS: Twenty-one hips (19 patients, 2 bilateral cases) were treated. The variables VAS, HHS as well as Lequesne improved significantly from T0 to T4 (at 12 months) with the best improvement between T0 and T1. At the same time, a reduction in NSAIDs monthly intake was registered. On the other hand, a significant improvement in Tegner scale was not observed. No adverse events were registered.
CONCLUSION: This study states that one cycle of HYADD4-G could be a safe and effective treatment in patients with FAI, showing significative results in term of pain control as well as hip functionality and quality of life up to 1 year.

Introduction

Femoroacetabular impingement (FAI) was firstly described in the 1990s,, and since that time has been increasingly recognized as a cause of groin pain and dysfunction. Nevertheless, the incidence of FAI in the general population is still unknown. A recent cohort study conducted in Netherlands analyzed 31.451 patients showing a prevalence of groin pain of 0.6% among which 17% was later clinically and radiologically diagnosed with FAI. Furthermore, several studies on asymptomatic volunteers presented prevalence rates of radiological characteristics of FAI ranging between 7 and 23%,.

FAI is caused by repetitive mechanical stress on a morphologically abnormal proximal femur and/or acetabulum during terminal range-of-motion of the hip. This pathological process eventually results in characteristic damage to the labrum and acetabular cartilage, and may predispose to hip osteoarthritis (OA),. Growing evidence has recently mounted over the role of FAI in the development of early OA, focusing on labral deterioration and labral calcification as part of this degenerative evolution.

Precise guidelines for the treatment of FAI have not been defined yet. Conservative measures including physical therapy, rest, core strengthening, sensory-motor skills improvement as well as pain control with nonsteroidal anti-inflammatories (NSAIDs) are the mainstays of nonsurgical treatments. When nonsurgical treatments show no benefit after 3 months or if the patient becomes refractory to conservative management, surgical intervention may be required.

Viscosupplementation (VS) by intra-articular injection of hyaluronic acid (HA) is proving to be safe and effective for pain control in patients affected from arthritis, especially in knee osteoarthritis. The latest OARSI guidelines state that intra-articular HA are considered Level 1B/Level 2, thus recommended, treatments for knee OA whereas the same treatment is not recommended for individuals with hip or polyarticular OA. Accordingly, Leite et al., after having conducted a systematic review and meta-analysis, do not recommend VS in hip OA given the scarce evidence of its efficacy against pain and disability up to 3 months and no difference at 6 months despite high evidence of safety compared to placebo. On the other hand, evidence on the possible use of VS in FAI is still limited: to our knowledge, the use of HA in the treatment of FAI has been investigated only by two studies,, both using a high molecular weight HA, and the efficacy of an hexadecylamide derivate of HA in FAI has never been investigated yet.

However, higher beneficial effects of intra-articular injection of a hexadecylamide HA derivative compared to unmodified 500–730 kDa HA in sheep models have been described in the literature. Particularly, it has been shown an improvement of gait, a stimulation of high molecular weight HA synthesis by the synovia, as well as a reduction in synovial hyperplasia in advanced OA,. Moreover, another in vitro study has shown better outcomes of derivatized HA compared with unmodified HA on both chondrocyte and synovial fibroblast expression of catabolic enzymes as well as inflammatory cytokines/mediators using human joint tissue cells.

Given these considerations, the purpose of this paper is to investigate safety and efficacy of one cycle of the HA derivative Hymovis (HYADD4-G) in patients affected from FAI syndrome.

Methods

Study design

This is a single-center, open label interventional study. 19 patients with clinical and radiological diagnosis of FAI were recruited, treated and evaluated prospectively for up to 1 year of follow-up. All the patients underwent a visitation with an orthopedic specialist. Furthermore, plain radiographs were performed to assess the grade of OA using Tonnis classification system,. Moreover, a magnetic resonance arthrography (MRA) was prescribed to verify the presence of a labral pathology or an acetabular cartilage loss, using the staging proposed by Czerny et al..

This study was conducted following the principles of the Declaration of Helsinki and with the patients’ permission expressed through a written consent.

Inclusion/exclusion criteria

Inclusion criteria were pain for at least 3 months as well as positivity to hip impingement test (FADDIR: flexion and internal rotation). Moreover, we included patients affected from CAM FAI measured with 45° flexion Dunn/Rippstein radiographic view showing an α-angle >55°, obtained to reveal pathomorphology of the anterior femoral head–neck junction,. Radiographic signs of acetabular over-coverage in anteroposterior pelvic view (cross-over sign, ischial spine sign, posterior wall sign), coxa profunda as well as acetabulum protrusion were also inclusion criteria for this study. Exclusion criteria were: α-angle ≤55°, age > 55 years, history of hip disease (slipped capital femoral epiphysis, Perthes disease, osteotomy, dysplasia), inflammatory, autoimmune and septic disease (rheumatoid arthritis, connective tissue disease, osteomyelitis), advanced radiographic hip OA (Tonnis ≥2), as well as previous intra-articular injection with steroids. The flow chart is showed in Figure 1.

Figure 1.

Figure showing the flow chart.

Outcome measurements

At baseline demographic, anthropometric and clinical data (sex, age, weight, height, BMI, symptoms duration, sport and work activities) were collected. All patients underwent two weekly intra-articular injection of Hymovis (HYADD4-G, Fidia Farmaceutici, Abano Terme, Italy) at baseline and after 7 days. The follow-up was set at the following stages: pretreatment (T0), 1 month (T1), 3 months (T2), 6 months (T3) and 12 months (T4), evaluating variations of functional score systems and considering monthly consumption of NSAIDs. Particularly, functional measures included pain during the previous week (visual analogue scale [VAS]), Harris Hip score (HHS), Lequesne Index (LI), Tegner activity level scale (TALS).

Operative technique

Hymovis is a derivative of HA obtained by controlled chemical synthesis (2% partial hexadecylamide). Its chemical structure lends it hygroscopic properties forming a hydrogel with excellent viscoelastic, lubricating as well as rheological properties.

Injections were performed using a musculo-skeletal ultrasound-guided procedure with a low frequency 3.5 − 7.5 MHz linear array probe in sterile conditions. The patient was positioned supine with heels joined and slightly externally rotated legs (10–20° degrees). Using an antero-inferior approach, HA was administered through a 20-G spinal needle inserted at the basis of the femoral neck. The HA intra-articular placement was visualized as a hyperechoic flow by ultrasounds (real time method). Patients were asked to rest for a month before resuming sporting activity.

Statistical analysis

The software used for statistical analysis were R software (R Core Team, 2017) and lmerTest package. All the treated patients were considered for statistical analysis, which was performed using a mixed effects model. Particularly, it is a statistical model containing both fixed effects as well as random effects, mostly useful in settings like longitudinal studies where repeated measurements are made on the same statistical units.

To statistically quantify this improvement, after model selection with the likelihood ratio test, the aforementioned linear mixed effects model was fitted for each outcome variable considering the following independent variables as fixed effects: time (five categories), age (in years), sex (=1 if male), height (in cm), weight (in Kg), side of lesion (=1 if left) as well as duration of symptoms (in months) at first visit. Since the model includes the effect of different intercepts and slope in time for each individual subject, the random slopes and intercepts of time were added.

Results

The demographic and clinical data of the patients included in the study are reported in Table 1. In 17 patients, hip impingement tests were positive on one side, while in 2 patients, both hips were affected, for a total of 19 patients and 21 hips treated. The FAI characteristics are reported in Table 2. The data collected in the follow-up after joint injections show a pattern of marked improvement with time, as can be inferred from Table 3, where means and standard deviations are reported for the different variables at different time points. The resulted model fits are summarized in Figures 2 and 3. p-values were obtained via Satterthwaite’s degrees of freedom method and are highlighted in bold when less than 0.05. Visual inspection of the residuals confirmed the goodness of fit of the aforementioned models.

Table 1.

Table showing patients’ demographic and clinical features.

		Range
Number	19
Age (years)	47 (s.d. 5.3)	(36–56)
Gender (F/M)	14/5
Weight (kg)	64.3 (s.d. 9.4)	(59–87)
Height (cm)	166.1 (s.d. 4.6)	160–174
BMI	23.3 (s.d. 3.4)	(19–32.7)
Hips treated	21a
Side (Lt/Rt)	10/11

a2 patients with bilateral FAI.

Table 2.

Table showing FAI characteristics.

		Range
Type (Cam/Pincer/Mixed)	14/3/4
α-angle (°)	68.6 (s.d.5.8)	(58–80)
Type of labral lesionsa:
Degeneration	2
Stage IA	0
Stage IB	0
Stage IIA	13
Stage IIB	0
Stage IIIA	6
Stage IIIB	0
Chondral lesions (N/Y)	4/17
Type of chondral lesionsb (2°,3°,4°)	8/8/1

astaging of lesions of the acetabular labrum by Czerny et al..

bchondral injury classification with the Outerbridge System.

Table 3.

Table showing means and standard deviations of Visual Analog Score (VAS), Harris Hip Score (HHS), Lequesne Index (LI), Tegner activity level scale (TALS) as well as NSAIDs monthly intake (number of pills) at each follow-up: pretreatment (T0), 1 month (T1), 3 months (T2), 6 months (T3) and 12 months (T4). p-values between t0 and t4 are summarized in the last line.

Time	Data Mean (SD) VAS	Mean (SD) HHS	Mean (SD) LI	Mean (SD) TALS	Mean (SD) NSAIDs monthly intake
t0	62.1 (15.2)	71.2 (9.67)	6.14 (4.64)	2.43 (1.12)	9.45 (9.50)
t1	40.5 (21.1)	80.8 (12.8)	2.86 (2.24)	2.81 (1.50)	2.55 (2.97)
t2	25.7 (14.0)	84.9 (9.90)	2.00 (1.79)	3.05 (1.43)	0.57 (0.75)
t3	17.6 (13.0)	89.1 (9.23)	1.24 (1.0)	2.86 (1.20)	0.24 (0.82)
t4	21.0 (14.5)	87.7 (9.35)	1.33 (1.15)	2.86 (1.20)	0.21 (0.54)
p-value	p < .0001	p < .0001	p < .0001	p = .54	p = .0003

Figure 2.

Model fit summaries for the outcome variables VAS, HHS and Lequesne.

Figure 3.

Model fit summaries for the outcome variables Tegner and NSAID intake.

Particularly, the slopes with respect to time for the variables VAS, HHS, Lequesne (Figure 4) and NSAIDs monthly intake (Figure 5) were highly significant (p < .0001; p < .0001; p < .0001; p = .0003). VAS averages decreased constantly from T0 to T3, and the average decrease over the whole follow-up was −10.53 for each time interval. HHS averages increased constantly from T0 to T3, and the average increase over the whole follow-up was 4.17 for each time interval. Lequesne index averages decreased constantly from T0 to T3, and the average decrease over the whole follow-up was −1.10 for each time interval. Monthly NSAIDs intake averages decreased constantly from T0 to T4, and the average decrease over the whole follow-up was −2.12 for each time interval. For all these variables, the steepest increase or decrease was observed between T0 and T1.

Figure 4.

Evolution of VAS, HHS and Lequesne during follow-up.

Figure 5.

Evolution of Tegner and NSAID intake during follow-up.

Tegner scale (Figure 5) did not show a significant improvement with time.

The quality of life measured considering sport and work activity also showed a marked improvement over time.

Discussion

HA holds mechanical effects and protective properties on articular cartilage commonly known respectively as viscosupplementation and biosupplementation.

Which lead to a long-lasting effect on articular surface. Specifically, HA improves the overall joint lubrication and viscoelastic properties of the articular cartilage, retaining higher amounts of fluid in the articular space together resulting in anti-inflammatory and anti-nociceptive effects,.

Multiple types of nerve ending have been identified within the labrum, reinforcing the fact that a torn labrum can be a primary cause of hip pain,. The number and type of nerves and organs in the labrum do not differ based on age. However, more unmyelinated nerve endings, those that sense pain, were found in the superior and anterior quarters of the labrum, the part more involved in the FAI.

Hexadecylamide derivative of HA is a highly viscoelastic hydrogel bioengineered using a proprietary process that increases lubrication and shock absorption properties, resulting in a natural hyaluronan similar to the human synovial fluid hyaluronan. The formulation allows the unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interaction, the non-crosslinked hexadecylamide derivative of HA shows increased elasticity, viscosity as well as a longer half-life in the joint.

Gomis et al. observed a reduction of nerve afferents mechanical-related impulse activity in intact guinea pig joints provided by hexadecylamide derivative of HA. Particularly, force transmission on articular mechanotransduction apparatus is likely reduced by its elastoviscous properties, leading to a decrease of the overall force transmission as well as sensory fibers response to mechanical forces. Moreover, hexadecylamide derivative of HA can likely bind to cell membrane receptors and interact with inflammatory mediators of damaged tissues, thus providing a direct analgesic effect. The aforementioned chemical interactions could explain the reduction of impulse activity as well as the consequent marked improvement of the variables analyzed in this study, after use of HYADD4-G.

According to this data, it appears reasonable to speculate that HYADD4-G has a direct effect on joint nociceptors reducing their activity. This effect is both related to its mechanical filter role associated with the aforementioned rheological properties, as well as to its chemical interaction with inflammatory cytokines present in the inflamed joint tissues, thus reducing their sensitizing effect on nociceptor terminals. HYADD-4 has been mainly studied as a treatment for knee and shoulder OA proving to be a safe and effective option for these conditions. Moreover, growing interest in HYADD-4 activity was raised when Zorzi et al. showed that this hexadecilamide derivate of HA leaded to a significant reduction in length and depth of meniscal knee lesions assessed with MRI compared with a control group.

To our knowledge this is the first evidence of the use of HYADD-4 in hip pathologies and only the third evaluating HA injections as a possible treatment for FAI. Our results are coherent with those of Abate et al. and Lee et al. in showing that VS with HA is a safe and efficient treatment for this condition. As a future perspective, it would be interesting to compare the efficacy of classical HA with hexadecilamide derivate to investigate the possible advantages of its peculiar composition and structure. In addition to this VS with HA, in the treatment of FAI, should be compared to other promising infiltrative techniques such as PRP that in recent meta-analysis as well as interventional studies showed similar if not superior results compared to HA in hip OA.

Limitations

Although this study shows positive results, several limitations must be addressed. A larger sample size would be preferred to avoid selection bias. Moreover, due to the lack of a placebo arm a potential placebo effect cannot be ruled out. However, since the efficacy of an hexadecylamide derivate of HA in FAI has never been investigated yet, the aim of this study is mainly to assess its effects on FAI as well as to give a starting point for further research.

Conclusions

Our results show that intra-articular injection of a HYADD4-G at baseline and after 7 days may provide good results improving hip function, reducing the pain as well as the functional impairment in daily living activities up to 12 months in patients affected from FAI. However, since none of the conservative modalities treat the underlying cause of FAI, surgery is indicated if symptoms persist.